What key experiences or clinical gaps motivated your focus on advancing prostate cancer diagnostics, particularly MRI-led ...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for ...
Diagnostic tools based on artificial intelligence are now making their way into Norwegian hospitals. AI can independently ...
Drs Dean Ornish and Peter Carroll presented their research on the effects of an intensive lifestyle program on outcomes for ...
Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, Jan. 29, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global AI medical ...
Various imaging modalities show low sensitivity for detecting pelvic lymph node invasion prior to surgery in patients with intermediate risk prostate cancer.
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI ...
They found the menopause is linked to a loss of brain grey matter - which is vital for mental functions, memory, emotions and ...
The Image-Guided Radiation Therapy market is driven by the rising global cancer prevalence and demand for precise, non-invasive treatments. Opportunities exist in advanced technology integrations like ...
Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results